SK bioscience Co., the biopharmaceutical arm of South Korea's SK Group, said Wednesday it has achieved a "final victory" in a ...

South Korean vaccine developer SK bioscience has won a final ruling in a patent dispute with Moderna (Nasdaq: MRNA) over key ...

SK Bioscience announced Wednesday that it has secured a definitive legal victory in its patent invalidation suit against Moderna, successfully challenging the biotech giant’s Korean patent related to ...

SK Bioscience CEO Ahn Jae-yong, left, and Sanofi's Jean-Francois Toussant, global head of vaccine research and development, pose for the photo after a signing ceremony. [SK BIOSCIENCE] SK ...

Sanofi has moved ahead with plans to challenge Pfizer and MSD for a piece of the market for pneumococcal vaccines, taking a 21-valent shot licensed from SK Biosciences into phase 3 testing.

South Korean biotech company SK Bioscience has completed a deal to acquire a controlling stake in the German company IDT Biologika, one of the ten largest global vaccine companies. This is reported in ...

SK bioscience announced on the 12th that it has begun shipping the flu vaccine 'Skycellflu' to southern hemisphere countries, including Southeast Asia and Latin America. The shipment quantity ...

Influenza vaccine SKYCellflu of SK bioscience on shipment at vaccine manufacturing plant L HOUSE This shipment marks the company's second export of influenza vaccines for Southern Hemisphere use, ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

SK bioscience, the biopharmaceutical arm of South Korea's SK Group, said on Wednesday it has achieved a "final victory" in a ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Got a new vaccine? Korea can make it for you.